Key Highlights
- On Thursday, November 19, 2026, PepGen (NASDAQ:PEPG) moved to USD 4.16 in intraday data, which is 8.82% higher. Searches located no company announcement from that day.
- A deal for 25 million shares priced at USD 5.00 on November 11, 2026, carried an expected gross of USD 125 million before fees.
- Phase 2 testing of PGN-EDODM1 produced a 46.5% mean splicing correction at the 10 mg/kg level, where five of six patients passed 20% and four went beyond 50%.
- Losses for the third quarter reached USD 19.4 million, while cash, equivalents and marketable securities stood at USD 104.8 million on September 30, 2026.
Shares Trade Under the Offering Price
PepGen (NASDAQ:PEPG) advanced to USD 4.16 during Thursday's session, November 19, 2026, in intraday trading, yet it still sits roughly 16.8% beneath the USD 5.00 offering level, a figure calculated from two published prices. The company revealed on November 11 an underwritten sale of 25 million common shares, including a 30-day underwriter option for up to 3.75 million more. Closing was anticipated on or about November 13, and the proceeds will support clinical development, Working Capital and general purposes. No dated announcement from November 17 through 19 was located, so this rise lacks a company-specific trigger, and thinly traded sub-USD 5 shares can move abruptly.
Data From the Trial Came First
PepGen works as a clinical-stage biotech, and its leading candidate PGN-EDODM1 is aimed at myotonic dystrophy type 1. On November 10 the company disclosed results from the 10 mg/kg group of the FREEDOM2-DM1 study, which showed mean splicing correction of 46.5%. Patients also reported gains in hand opening speed, grip strength and walking pace, and no serious adverse events or dose-limiting toxicities emerged. A monitoring board endorsed moving to the 12.5 mg/kg group next, a cohort that has completed enrollment, and expects its results in the first half of 2027. Open-label extension information is planned for January 2027. The offering came a day later, a typical sequence for small drug developers that raise money after encouraging findings.
Runway Versus the Partial Hold and Dilution
At September 30 the company held USD 104.8 million in cash, equivalents and marketable securities, a level management tied to operations running into 2028. Including the USD 125 million gross, the sum comes to approximately USD 229.8 million before expenses, a calculated figure that ignores subsequent outlays. The third-quarter loss amounted to USD 19.4 million, which works out to USD 0.28 a share, and Research and Development costs totaled USD 14.5 million. The chief hazard is a partial FDA clinical hold issued in March 2026 following nonclinical findings in mice, and a potential end-of-Phase 2 meeting slated for the second half of 2027 hinges on lifting it. New shares also dilute current holders, and quoted prices for low-priced stocks can reverse quickly.
Where Things Stand
Today's advance looks like a rebound inside a wider financing story, because the search turned up no company notice dated November 19. PepGen (NASDAQ:PEPG) is at USD 4.16 after gaining 8.82%, which keeps it under the USD 5.00 that buyers paid in the deal. Supportive factors include promising splicing figures, a USD 125 million raise and a cash runway that already reached into 2028. Offsetting factors are the open FDA partial hold, dilution and early-stage trial uncertainty. Monitor the offering's closing, any movement on the hold and the January 2027 extension update.






Please wait processing your request...